Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 2
2013 4
2014 4
2015 4
2016 5
2017 8
2018 5
2019 6
2020 4
2021 1
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Individualized Pazopanib Dosing-Letter.
Bellesoeur A, Boudou-Rouquette P, Thomas-Schoemann A, Joly C, Tlemsani C, Vidal M, Goldwasser F, Blanchet B. Bellesoeur A, et al. Among authors: thomas schoemann a. Clin Cancer Res. 2017 Oct 15;23(20):6377. doi: 10.1158/1078-0432.CCR-17-1873. Clin Cancer Res. 2017. PMID: 29030334 No abstract available.
Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.
Puszkiel A, Noé G, Bellesoeur A, Kramkimel N, Paludetto MN, Thomas-Schoemann A, Vidal M, Goldwasser F, Chatelut E, Blanchet B. Puszkiel A, et al. Among authors: thomas schoemann a. Clin Pharmacokinet. 2019 Apr;58(4):451-467. doi: 10.1007/s40262-018-0703-0. Clin Pharmacokinet. 2019. PMID: 30094711 Review.
Drug interactions with solid tumour-targeted therapies.
Thomas-Schoemann A, Blanchet B, Bardin C, Noé G, Boudou-Rouquette P, Vidal M, Goldwasser F. Thomas-Schoemann A, et al. Crit Rev Oncol Hematol. 2014 Jan;89(1):179-96. doi: 10.1016/j.critrevonc.2013.08.007. Epub 2013 Aug 28. Crit Rev Oncol Hematol. 2014. PMID: 24041628 Review.
Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
Boudou-Rouquette P, Tlemsani C, Blanchet B, Huillard O, Jouinot A, Arrondeau J, Thomas-Schoemann A, Vidal M, Alexandre J, Goldwasser F. Boudou-Rouquette P, et al. Among authors: thomas schoemann a. Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1433-1444. doi: 10.1080/17425255.2016.1225038. Epub 2016 Aug 24. Expert Opin Drug Metab Toxicol. 2016. PMID: 27556889 Review.
Predictive factors associated with pemetrexed acute toxicity.
Bonnet M, Jouinot A, Boudou-Rouquette P, Seif V, Villeminey C, Arrondeau J, Vidal M, Batista R, Wislez M, Blanchet B, Goldwasser F, Thomas-Schoemann A. Bonnet M, et al. Among authors: thomas schoemann a. Eur J Clin Pharmacol. 2023 May;79(5):635-641. doi: 10.1007/s00228-023-03478-4. Epub 2023 Mar 23. Eur J Clin Pharmacol. 2023. PMID: 36951965
Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.
Arrondeau J, Huillard O, Tlemsani C, Cessot A, Boudou-Rouquette P, Blanchet B, Thomas-Schoemann A, Vidal M, Tigaud JM, Durand JP, Alexandre J, Goldwasser F. Arrondeau J, et al. Among authors: thomas schoemann a. Expert Opin Investig Drugs. 2015 May;24(5):673-87. doi: 10.1517/13543784.2015.1005736. Epub 2015 Jan 20. Expert Opin Investig Drugs. 2015. PMID: 25599887 Review.
Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).
Slimano F, Baudouin A, Zerbit J, Toulemonde-Deldicque A, Thomas-Schoemann A, Chevrier R, Daouphars M, Madelaine I, Pourroy B, Tournamille JF, Astier A, Ranchon F, Cazin JL, Bardin C, Rioufol C. Slimano F, et al. Among authors: thomas schoemann a. Cancer Treat Rev. 2020 Aug;88:102063. doi: 10.1016/j.ctrv.2020.102063. Epub 2020 Jun 23. Cancer Treat Rev. 2020. PMID: 32623296 Free PMC article. Review.
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
Bretagne M, Boudou-Rouquette P, Huillard O, Thomas-Schoemann A, Chahwakilian A, Orvoen G, Arrondeau J, Tlemsani C, Cessot A, Cabanes L, Blanchet B, Coriat R, Alexandre J, Goldwasser F. Bretagne M, et al. Among authors: thomas schoemann a. Bull Cancer. 2016 Mar;103(3):259-72. doi: 10.1016/j.bulcan.2015.10.020. Epub 2016 Jan 29. Bull Cancer. 2016. PMID: 26832420 Review. French.
Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.
Tlemsani C, Huillard O, Arrondeau J, Boudou-Rouquette P, Cessot A, Blanchet B, Thomas-Schoemann A, Coriat R, Durand JP, Giroux J, Alexandre J, Goldwasser F. Tlemsani C, et al. Among authors: thomas schoemann a. Expert Opin Drug Metab Toxicol. 2015 May;11(5):785-94. doi: 10.1517/17425255.2015.1030392. Epub 2015 Mar 25. Expert Opin Drug Metab Toxicol. 2015. PMID: 25809423 Review.
44 results